Fuster et al., 2008 - Google Patents
Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional …Fuster et al., 2008
View PDF- Document ID
- 13355680465162974719
- Author
- Fuster D
- Duch J
- Paredes P
- Velasco M
- Munoz M
- Santamaría G
- Fontanillas M
- Pons F
- Publication year
- Publication venue
- Journal of Clinical Oncology
External Links
Snippet
Purpose To evaluate the utility of positron emission tomography (PET) and [18F] fluorodeoxyglucose in the initial staging of large primary breast tumors. Patients and Methods This prospective study was approved by the ethics committee, and all patients gave …
- 238000002600 positron emission tomography 0 title abstract description 81
Classifications
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/30—Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
- G06F19/32—Medical data management, e.g. systems or protocols for archival or communication of medical images, computerised patient records or computerised general medical references
- G06F19/321—Management of medical image data, e.g. communication or archiving systems such as picture archiving and communication systems [PACS] or related medical protocols such as digital imaging and communications in medicine protocol [DICOM]; Editing of medical image data, e.g. adding diagnosis information
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/507—Clinical applications involving determination of haemodynamic parameters, e.g. perfusion CT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/50—Clinical applications
- A61B6/502—Clinical applications involving diagnosis of breast, i.e. mammography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
- A61B6/02—Devices for diagnosis sequentially in different planes; Stereoscopic radiation diagnosis
- A61B6/03—Computerised tomographs
- A61B6/032—Transmission computed tomography [CT]
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10072—Tomographic images
- G06T2207/10084—Hybrid tomography; Concurrent acquisition with multiple different tomographic modalities
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fuster et al. | Preoperative staging of large primary breast cancer with [18F] fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures | |
Ruers et al. | Value of positron emission tomography with [F-18] fluorodeoxyglucose in patients with colorectal liver metastases: a prospective study | |
Ng et al. | Prospective study of [18F] fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck | |
Meltzer et al. | Whole-body FDG positron emission tomographic imaging for staging esophageal cancer: comparison with computed tomography | |
Motosugi et al. | Detection of pancreatic carcinoma and liver metastases with Gadoxetic acid–enhanced MR imaging: comparison with contrast-enhanced multi–detector row CT | |
Morris et al. | Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer | |
Eubank et al. | Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer | |
Drieskens et al. | FDG-PET for preoperative staging of bladder cancer | |
Reinhardt et al. | Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N-and M-staging of malignant melanoma: experience with 250 consecutive patients | |
Yoon et al. | CT, MR, US, 18 F-FDG PET/CT, and their combined use for the assessment of cervical lymph node metastases in squamous cell carcinoma of the head and neck | |
Antoch et al. | Accuracy of whole-body dual-modality fluorine-18–2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET | |
Heriot et al. | Does positron emission tomography change management in primary rectal cancer? A prospective assessment | |
Nakamoto et al. | Delayed 18F‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas | |
Bar-Shalom et al. | Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management | |
Jeong et al. | Does CT of thymic epithelial tumors enable us to differentiate histologic subtypes and predict prognosis? | |
Schilling et al. | Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging | |
Choi et al. | Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging | |
Kulinna et al. | Staging of rectal cancer: diagnostic potential of multiplanar reconstructions with MDCT | |
Takanami et al. | Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules | |
Chen et al. | Comparison of 18F-Fluciclovine PET/CT and 99mTc-MDP bone scan in detection of bone metastasis in prostate cancer | |
Weir et al. | The value of FDG positron emission tomography in the management of patients with breast cancer | |
Pfluger et al. | PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT | |
Kwak et al. | Diagnostic value of FDG-PET/CT for lymph node metastasis of colorectal cancer | |
Veit-Haibach et al. | FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy | |
Litmanovich et al. | Unexpected foci of 18 F-FDG uptake in the breast detected by PET/CT: incidence and clinical significance |